| Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments |
WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On May 7, 2025, Monopar presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline) at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025, a leading global conference in liver disease. |
globenewswire.com |
2025-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 |
WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025, one of the most prominent global conferences in liver disease. Monopar's late-breaker poster presentation is available at the following link: https://www.monopartx.com/pipeline/ALXN1840/EASL-poster-may-2025. |
globenewswire.com |
2025-05-07 06:30:00 |
Czytaj oryginał (ang.) |
| Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 |
WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease has been accepted for a late-breaker poster presentation at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025. EASL is recognized as one of the premier events in the hepatology space and will be held in Amsterdam, Netherlands from May 7 – 10, 2025. |
globenewswire.com |
2025-04-29 12:00:00 |
Czytaj oryginał (ang.) |
| Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments |
WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced fourth quarter and full-year 2024 financial results and summarized recent developments. |
globenewswire.com |
2025-03-31 12:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going |
Monopar Therapeutics (MNPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2025-03-21 11:50:29 |
Czytaj oryginał (ang.) |
| Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics |
Monopar's pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease NORTH CHICAGO, Ill. , Jan. 23, 2025 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science announced that Monopar Therapeutics is the latest biotech company to join the Helix 51 biomedical incubator community. |
prnewswire.com |
2025-01-23 15:10:00 |
Czytaj oryginał (ang.) |
| MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN |
Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate. |
zacks.com |
2025-01-02 13:07:14 |
Czytaj oryginał (ang.) |
| What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 |
Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025. |
zacks.com |
2024-12-26 13:32:08 |
Czytaj oryginał (ang.) |
| Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways |
MNPR-101-Lu is being developed in a phase 1 study to target advanced solid tumor patients with uPAR expression. MNPR-101-Zr is being used as an imaging agent to determine which advanced solid tumor patients is likely to respond to MNPR-101-Lu in a phase 1 study. The global solid tumor cancer treatment market size is projected to hit around $532.42 billion by 2032; uPAR expression is high in a variety of types of solid tumors. |
seekingalpha.com |
2024-12-23 16:23:40 |
Czytaj oryginał (ang.) |
| Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants |
WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 798,655 shares of its common stock at an offering price of $23.79 per share. In addition to the shares sold in the registered offering, Monopar announced the concurrent pricing of a private placement of pre-funded warrants to purchase 882,761 shares of common stock at a purchase price of $23.789 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to Monopar from the registered offering and private placement, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be $40 million. The offering is expected to close on or about December 23, 2024, subject to customary closing conditions. |
globenewswire.com |
2024-12-20 11:00:00 |
Czytaj oryginał (ang.) |
| Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu |
WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical combines MNPR-101, Monopar's antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177. uPAR is involved in tumor growth and metastasis, and is found in some of the most aggressive, deadly cancers, including pancreatic, ovarian, triple negative breast, and colorectal cancers. |
globenewswire.com |
2024-12-05 18:21:00 |
Czytaj oryginał (ang.) |
| Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference |
WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar's Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference. |
globenewswire.com |
2024-12-03 10:00:00 |
Czytaj oryginał (ang.) |
| 3 Momentum Stocks Soaring Into 2025 and Beyond |
Investors favoring a short horizon and possessing a fair amount of risk tolerance sometimes look to stocks that have already been trending upward in an effort to capitalize on their momentum. This investment strategy often looks more toward price movement than it does the fundamentals of a company. |
marketbeat.com |
2024-12-03 09:01:43 |
Czytaj oryginał (ang.) |
| What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing' |
Monopar Therapeutics (MNPR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2024-12-02 16:25:35 |
Czytaj oryginał (ang.) |
| What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing' |
Monopar Therapeutics (MNPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2024-12-02 16:25:27 |
Czytaj oryginał (ang.) |
| Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus |
Monopar Therapeutics is a clinical-stage biotech focused on radiopharmaceuticals for oncology and recently expanded into rare diseases with ALXN-1840. MNPR's oncology pipeline includes MNPR-101-Zr for diagnostics and MNPR-101-Lu/Ac for therapeutic applications, both in the early development stages. ALXN-1840, a Phase 3 asset for Wilson disease, diversifies MNPR's portfolio but does not directly complement its oncology focus. |
seekingalpha.com |
2024-11-25 21:53:28 |
Czytaj oryginał (ang.) |
| Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments |
In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare Disease Two Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers |
globenewswire.com |
2024-11-08 10:00:00 |
Czytaj oryginał (ang.) |
| Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock |
WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the closing of its previously announced best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. |
globenewswire.com |
2024-10-30 15:42:00 |
Czytaj oryginał (ang.) |
| Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock |
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of its best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The offering is expected to close on October 30, 2024, subject to satisfaction of customary closing conditions. |
globenewswire.com |
2024-10-28 23:15:00 |
Czytaj oryginał (ang.) |
| Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock |
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that it intends to offer to sell shares of its common stock in a best efforts public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. |
globenewswire.com |
2024-10-28 18:00:00 |
Czytaj oryginał (ang.) |
| Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock? |
The stock price of Monopar Therapeutics (NASDAQ: MNPR), a clinical-stage biopharmaceutical company, skyrocketed from levels of $5.25 on Monday, October 21, to $32.66 on Thursday, October 24, before falling to around $17 now. The 6x rise in a matter of days can be attributed to a major licensing development for Monopar. |
forbes.com |
2024-10-28 15:29:34 |
Czytaj oryginał (ang.) |
| Monopar Therapeutics Skyrockets 400% on Licensing Deal |
Monopar Therapeutics NASDAQ: MNPR saw its stock skyrocket over 400% on Thursday after announcing a licensing deal with AstraZeneca. By 2 PM, the stock had traded over 10 million shares, far above its usual daily volume of 800,000. |
marketbeat.com |
2024-10-25 12:12:11 |
Czytaj oryginał (ang.) |
| Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder |
Monopar Therapeutics Inc. MNPR stock is skyrocketing on Thursday. |
benzinga.com |
2024-10-24 17:18:38 |
Czytaj oryginał (ang.) |
| Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate |
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced an agreement with Alexion, AstraZeneca Rare Disease, for a license to ALXN-1840 for Wilson disease. The drug candidate showed promising results in a Phase 3 trial, meeting its primary endpoint. Monopar will now handle global development, addressing unmet needs in Wilson disease treatment. |
globenewswire.com |
2024-10-24 11:00:00 |
Czytaj oryginał (ang.) |
| Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 |
WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the clinical and preclinical development of its novel first-in-class lead radiopharma program based on MNPR-101 at the European Association of Nuclear Medicine (EANM) 2024 Annual Congress held in Hamburg, Germany. MNPR-101-Lu radiation dosimetry analytics using human data from MNPR-101-Zr show a favorable organ safety profile at high Lu-177 therapeutic dose levels. The slides for Monopar's oral presentation can be found at the following link: https://www.monopartx.com/pipeline/mnpr-101/eanm24-ppt. |
globenewswire.com |
2024-10-22 12:00:00 |
Czytaj oryginał (ang.) |
| Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers |
WILMETTE, Ill., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the filing of a provisional patent covering new therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotopes with targeting agents, including Monopar's uPAR targeting antibody MNPR-101. |
globenewswire.com |
2024-10-15 12:00:00 |
Czytaj oryginał (ang.) |